COVID-19 Resurgence in 2025: India’s Continuing Public Health Challenge

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 02 | 02 | Page :
    By

    Satish Kumar Sarankar,

  1. Professor, Faculty of Pharmacy, Mansarovar Global University, Sehore, M.P. 466111, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_201841’);});Edit Abstract & Keyword

The year 2025 has witnessed the resurgence of COVID-19, reigniting concerns at both global and national levels regarding the persistent threat posed by SARS-CoV-2. In early 2025, India witnessed a moderate resurgence of COVID‑19, characterized by the emergence of Omicron sub-variants and a rise in mild-to-moderate infections. As of mid-June, active COVID‑19 cases in India totaled approximately 6,000–7,400, with hotspots in Kerala (~2,100 cases), Delhi (~600), Maharashtra (~500), and several other states. The Indian SARS-CoV-2 Genomics Consortium (INSACOG) has identified key sub-lineages including JN.1, LF.7, NB.1.8.1, and recently XFG. These variants are associated with immune evasion and increased transmissibility, though current data indicate cases remain predominantly mild, with low hospitalization and death rates. India’s diagnostic efforts include scaling next-generation RT-PCR, antigen testing, and expanded genomic sequencing. Therapeutic protocols adhere to WHO recommendations, incorporating antivirals, immunomodulators, and oxygen therapy. Most cases are managed on an outpatient basis due to limited severity. India’s vaccination campaign, totaling over 2.4 billion doses, has encountered booster gaps. Variants under monitoring have prompted targeted booster drives, especially for high-risk groups. Fresh public health measures, mask advisories, reinforced surveillance, and state-led containment efforts aim to curb further spread. This review provides a detailed assessment of the evolving COVID-19 situation in India, outlining current challenges, national response efforts, and future directions to mitigate the ongoing health crisis.

Keywords: COVID-19 Resurgence, COVID-19 India 2025, Omicron Sub-lineages 2025, Pandemic Preparedness India, India’s Vaccine Development, Pandemic Resilience India

How to cite this article:
Satish Kumar Sarankar. COVID-19 Resurgence in 2025: India’s Continuing Public Health Challenge. International Journal of Tropical Medicines. 2025; 02(02):-.
How to cite this URL:
Satish Kumar Sarankar. COVID-19 Resurgence in 2025: India’s Continuing Public Health Challenge. International Journal of Tropical Medicines. 2025; 02(02):-. Available from: https://journals.stmjournals.com/ijtm/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_201841’);});Edit

References

  1. World Health Organization (WHO). COVID-19 global epidemiological updates. Geneva: WHO; 2023.
  2. Indian Council of Medical Research (ICMR). COVID-19 seroprevalence studies. New Delhi: ICMR; 2023.
  3. Indian SARS-CoV-2 Genomics Consortium (INSACOG). Variant surveillance updates. New Delhi: INSACOG; 2025.
  4. Integrated Disease Surveillance Programme (IDSP). COVID-19 weekly reports. New Delhi: Ministry of Health and Family Welfare; 2025.
  5. Indian Council of Medical Research (ICMR). COVID-19 response and diagnostic strategies. New Delhi: ICMR; 2024.
  6. Ministry of Health and Family Welfare (MoHFW). COVID-19 resurgence response guidelines. New Delhi: MoHFW; 2025.
  7. United Nations Children’s Fund (UNICEF). Vaccine hesitancy and COVID-19 communication challenges in India. New Delhi: UNICEF; 2024.
  8. Kumar R, Singh V, Patel A. Waning immunity and COVID-19 reinfections in India. Indian J Med Res. 2025;161(2):102–10.
  9. Council of Scientific and Industrial Research (CSIR). National wastewater surveillance for COVID-19 trends. New Delhi: CSIR; 2024.
  10. World Health Organization (WHO). Therapeutic guidelines for COVID-19 management. Geneva: WHO; 2024.
  11. AYUSH Ministry. Guidelines for integration of Ayurveda in COVID-19 care. New Delhi: Government of India; 2024.
  12. Singh S, Sharma P. Exploring Ayurvedic interventions for COVID-19 recovery. J Ayurveda Integr Med. 2025;16(1):45–53.
  13. Indian Council of Medical Research (ICMR). Pipeline therapeutics for SARS-CoV-2. New Delhi: ICMR; 2025.
  14. Shionogi Pharmaceuticals. Ensitrelvir clinical trial results. Tokyo: Shionogi; 2024.
  15. Bharat Biotech. Development of variant-specific COVID-19 vaccines. Hyderabad: Bharat Biotech; 2025.
  16. Serum Institute of India. Development of next-generation COVID-19 boosters. Pune: Serum Institute; 2025.
  17. World Health Organization (WHO). COVID-19 vaccination strategy updates. Geneva: WHO; 2024.
  18. Kerala Health Department. State-level COVID-19 preparedness guidelines. Thiruvananthapuram: Government of Kerala; 2025.
  19. Integrated Disease Surveillance Programme (IDSP). Surveillance strategy for emerging infections. New Delhi: Ministry of Health and Family Welfare; 2024.
  20. Ministry of Health and Family Welfare (MoHFW). National COVID-19 vaccination updates. New Delhi: MoHFW; 2024.
Ahead of Print Subscription Review Article
Volume 02
02
Received 24/06/2025
Accepted 04/08/2025
Published 08/08/2025
Publication Time 45 Days
82

[last_name]

My IP

PlumX Metrics